Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine

Future Microbiology

Volumn 10, Issue 8, 2015, Pages 1271-1281

  Jackson, Sarah S ^a   Chen, Wilbur H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; BACTERIUM ANTIBODY; LIVE VACCINE; VACCINE;

ANTIBODY RESPONSE; ARTICLE; CHOLERA; COLONY FORMING UNIT; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INDUSTRIALIZATION; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; SINGLE DRUG DOSE; BLOOD; CLINICAL TRIAL (TOPIC); ECONOMICS; IMMUNIZATION; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; TRAVEL; VIBRIO CHOLERAE;

ADMINISTRATION, ORAL; ANTIBODIES, BACTERIAL; CHOLERA; CHOLERA VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNIZATION SCHEDULE; PROSPECTIVE STUDIES; TRAVEL; VACCINE POTENCY; VACCINES, ATTENUATED; VIBRIO CHOLERAE;

EID: 84940657869     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/FMB.15.51     Document Type: Article

References (55)

1. Cholera 2013. Wkly Epidemiol. Rec. 89(31), 345-355 (2014
2. Ali M, Lopez AL, You YA et al. The global burden of cholera. Bull. World Health Organ. 90(3), 209-218a (2012
3. Clemens J, Holmgren J. Urgent need of cholera vaccines in public health-control programs. Future Microbiol. 4(4), 381-385 (2009
4. Cholera vaccines: WHO position paper. Wkly Epidemiol. Rec. 85(13), 117-128 (2010
5. Levine MM, Kaper JB. Live oral vaccines against cholera: an update. Vaccine 11(2), 207-212 (1993
6. Lopez AL, Gonzales ML, Aldaba JG, Nair GB. Killed oral cholera vaccines: history, development and implementation challenges. Ther. Adv. Vaccines 2(5), 123-136 (2014
7. Ali M, Sur D, You YA et al. Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India. Clin. Infect. Dis. 56(8), 1123-1131 (2013
8. Taylor DN, Cardenas V, Sanchez JL et al. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru. J. Infect. Dis. 181(5), 1667-1673 (2000
9. Sanchez JL, Vasquez B, Begue RE et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 344(8932), 1273-1276 (1994
10. Charles RC, Hilaire IJ, Mayo-Smith L et al. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti. PLoS Negl. Trop. Dis. 8(5), 1-8 (2014
11. Luquero FJ, Grout L, Ciglenecki I et al. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N. Engl. J. Med. 370(22), 2111-2120 (2014
12. Saha A, Chowdhury MI, Khanam F et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 29(46), 8285-8292 (2011
13. Saha A, Chowdhury MI, Nazim M et al. Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children. Vaccine 31(4), 647-652 (2013
14. Clemens JD, Sack DA, Rao MR et al. Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area. J. Infect. Dis. 166(5), 1029-1034 (1992
15. Sur D, Lopez AL, Kanungo S et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 374(9702), 1694-1702 (2009
16. Bhattacharya SK, Sur D, Ali M et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebocontrolled trial. Lancet Infect. Dis. 13(12), 1050-1056 (2013
17. Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. Lancet 379(9835), 2466-2476 (2012
18. Chen W, Cohen M, Kirkpatrick B et al. Single-dose live attenuated oral cholera vaccine (CVD 103-HgR) protects against cholera at 10 days following vaccination: results of a Vibrio cholerae O1 El Tor Inaba challenge study. Presented at: ASTMH 63rd Annual Meeting. LA, USA, November 2014
19. Chen WH, Greenberg RN, Pasetti MF et al. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. Clin. Vaccine Immunol. 21(1), 66-73 (2014
20. ClinicalTrials.gov identifier: NCT02094586. www.clinicaltrials.gov
21. PaxVax. PaxVax announces primary endpoints met in Phase 3 Cholera Vaccine Trial. Press Release. http://www.paxvax.com
22. Levine MM, Kaper JB. Live oral cholera vaccine: from principle to product. Bull. Inst. Pasteur 93, 243-253 (1995
23. Viret J, Dietrich G, Favre D. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Vaccine 22(19), 2457-2469 (2004
24. Lagos R, San Martin O, Wasserman SS et al. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. Pediatr. Infect. Dis. J. 18(7), 624-630 (1999
25. Tacket CO, Losonsky G, Nataro JP et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD l03-HgR. J. Infect. Dis. 166(4), 837 (1992
26. Kotloff KL, Wasserman SS, O'Donnell S, Losonsky GA, Cryz SJ, Levine MM. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebocontrolled, double-blind crossover trial. Infect. Immun. 60(10), 4430-4432 (1992
27. Tacket CO, Cohen MB, Wasserman SS et al. Randomized, double-blind, placebocontrolled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect. Immun. 67(12), 6341-6345 (1999
28. Cryz SJ Jr, Levine MM, Kaper JB, Fürer E, Althaus B. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine 8(6), 577-580 (1990
29. Cryz SJ Jr, Levine MM, Losonsky G, Kaper JB, Althaus B. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults. Infect. Immun. 60(9), 3916-3917 (1992
30. Cryz SJ Jr, Que JU, Levine MM, Wiedermann G, Kollaritsch H. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults. Infect. Immun. 63(4), 1336-1339 (1995
31. Kollaritsch H, Furer E, Herzog C, Wiedermann G, Que JU, Cryz SJ Jr. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines. Infect. Immun. 64(4), 1454-1457 (1996
32. Migasena S, Pitisuttitham P, Prayurahong B et al. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect. Immun. 57(11), 3261-3264 (1989
33. Su-Arehawaratana P, Singharaj P, Taylor DN et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis. 165(6), 1042-1048 (1992
34. Suharyono, Simanjuntak C. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-yearold. Lancet 340(8821), 689 (1992
35. Simanjuntak CH, O'Hanley P, Punjabi NH et al. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24-To 59-month-old Indonesian children. J. Infect. Dis. 168(5), 1169-1176 (1993
36. Gotuzzo E, Butron B, Seas C et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 61(9), 3994-3997 (1993
37. Lagos R, Avendano A, Prado V et al. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect. Immun. 63(2), 707-709 (1995
38. Perry RT, Plowe CV, Koumare B et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull. World Health Organ. 76(1), 63-71 (1998
39. Calain P, Chaine JP, Johnson E et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 22(19), 2444-2451 (2004
40. Levine MM, Kaper JB, Herrington D et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 2(8609), 467-470 (1988
41. Losonsky GA, Tacket CO, Wasserman SS, Kaper JB, Levine MM. Secondary Vibrio cholerae-specific cellular antibody responses following wild-Type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect. Immun. 61(2), 729-733 (1993
42. Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J. Infect. Dis. 201(11), 1607-1610 (2010
43. Ketley JM, Michalski J, Galen J, Levine MM, Kaper JB. Construction of genetically marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol. Lett. 111(1), 15-21 (1993
44. Favre D, Struck MM, Cryz SJ Jr, Viret JF. Further molecular characterization and stability of the live oral attenuated cholera vaccine strain CVD103-HgR. Vaccine 14(6), 526-531 (1996
45. Kaper JB, Michalski J, Ketley JM, Levine MM. Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR. Infect. Immun. 62(4), 1480-1483 (1994
46. von Seidlein L, Xuan-Yi Wang, Macuamule A et al. Is HIV infection associated with an increased risk for cholera? Findings from a case-control study in Mozambique. Trop. Med. Int. Health. 13(5), 683-688 (2008
47. Mushayabasa S, Bhunu CP. Is HIV infection associated with an increased risk for cholera? Insights from a mathematical model. BioSystems 109(2), 203-213 (2012
48. Rey JL, Milleliri JM, Soares JL et al. HIV seropositivity and cholera in refugee children from Rwanda. AIDS 9(10), 1203-1204 (1995
49. UN Joint Programme on HIV/AIDS (UNAIDS): The Gap Report: 2014. ISBN 978-92-9253-062-4 (2014). http://www.unaids.org
50. Richie EE, Punjabi NH, Sidharta YY et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18(22), 2399-2410 (2000
51. Ali M, Emch M, von Seidlein L et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366(9479), 44-49 (2005
52. Longini IM Jr, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD. Controlling endemic cholera with oral vaccines. PLoS Med. 4(11), e336 (2007
53. Mackinder M. PaxVax will seek FDA approval of single-dose cholera vaccine. Vaccine News Daily (8 December 2014). http://vaccinenewsdaily.com
54. ClinicalTrials.gov identifier: NCT02100631. www.clinicaltrials.gov
55. ClinicalTrials.gov identifier: NCT02145377. www.clinicaltrials.gov